At P & G in studies of more than six months after surgery in postmenopausal women, those who received a placebo said satisfying sexual activity increased by an average of 19% compared with an increase of 73% for users of Intrinsa patch. In the placebo group, women had an average increase of satisfying sexual episodes of 0.5 per month, while the patches had an average increase of 1.9 episodes per month.

The patch was granted a license from the European Medicines Agency in July and is available in the National Health Service of the United Kingdom from March 2007. Initially only available on prescription for postmenopausal women with diagnosed sexual problems.

However, in December 2004 the United States the 14 members of the Food and Drug Administration (FDA) advisory committee’s consultants also vote for Reproductive Health Drugs Fast unanimously rejected Procter and Gamble-item request on Intrinsa based on information on the use of the label. In Canada, post-menopausal women have been able to obtain government approval testosterone treatment since 2002. In Australia, post-menopausal women can use Organon testosterone implants must be surgically inserted and last three to six months.